Meta-Analysis Reveals Association Between IGF-I and IGFBP-3 with Premenopausal Breast Cancer Risk

Strategic Insights -

Researchers at the Aichi Cancer Center in Japan conducted a meta-analysis to investigate the association between circulating insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3, and the risk of premenopausal breast cancer. The study, published in the International Journal of Cancer, analyzed data from seven nested case-control and population-based case-control studies, including 688 premenopausal incident breast cancer cases and 1,366 controls. The results showed that women with higher circulating levels of IGF-I had a marginally significant increased risk of breast cancer, while no significant difference was observed for IGFBP-3.

Key Takeaways:

  • The meta-analysis included 688 premenopausal incident breast cancer cases and 1,366 controls from seven nested case-control and population-based case-control studies published between January 1990 and March 2003.
  • The studies considered as confounders other than IGF-I or IGFBP-3, which were the major source of variation in the analysis.
  • The results showed that women with higher circulating levels of IGF-I had a marginally significant increased risk of breast cancer with an odds ratio (OR) of 1.74 (95% confidence interval (CI)=0.97-3.13; P = .06).
  • No significant difference was observed for IGFBP-3 group (OR=1.60; 95% CI=0.84-3.02; P = .15).
  • The study's findings did not draw a conclusive picture regarding the association between circulating IGF-I levels and the risk of premenopausal breast cancer.
  • The results suggest a potential role of IGF-I in mammary cell carcinogenesis, but further research is needed to confirm the observations.

Statistics:

  • 688 premenopausal incident breast cancer cases were included in the analysis.
  • 1,366 controls were included in the analysis.
  • The studies considered as confounders other than IGF-I or IGFBP-3.
  • The OR for IGF-I was 1.74 (95% CI=0.97-3.13; P = .06).
  • The OR for IGFBP-3 was 1.60 (95% CI=0.84-3.02; P = .15).

Sources:

  • Sugumar, A., et al. (2004). Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: A meta-analysis of literature. International Journal of Cancer, 111(2), 293-297.
  • Health & Medicine Week editors. (2004). Meta-analysis reveals association between IGF-I and IGFBP-3 with premenopausal breast cancer risk. Health & Medicine Week, via NewsRx.com & NewsRx.net.